摘要
多聚N-(2-羟丙基)甲基丙烯酰胺(HPMA)-抗肿瘤药物偶合物可通过靶向分子及肿瘤细胞的增强渗透和滞留效应实现药物的靶向治疗,显著减少传统药物全身毒副作用,以其独特的优势成为目前抗肿瘤药物的研究热点之一。本文对多聚HPMA-抗肿瘤药物偶合物的组成及近几年来的临床前和临床应用研究现状和前景进行综述。
Poly-N-（2-hydroxypropyl） methacrylamide （HPMA）-anticancer drug conjugates can realize drugs targeting to tumors and significantly reduces drug systemic side effects, through targeted molecular or enhanced penetration and retention effect （EPR）. Thus, its unique advantages make it become one of the hotspots of the anticancer drug research. In this paper, based on the composition of poly-HPMA-anticancer drug conjugates, the polymer main chain, targeting molecules, connecting chain and the active drug, applied research advances and application prospects of poly-HPMA-anticancer drug conjugates are reviewed.
出处
《国际药学研究杂志》
CAS
2012年第3期204-209,共6页
Journal of International Pharmaceutical Research
